Helicobacter pylori (H. pylori) is a type of bacteria that can infect the stomach and cause various digestive problems, such as gastritis, peptic ulcers, and stomach cancer. H. pylori infection can cause a variety of gastrointestinal symptoms, Including abdominal pain, nausea, vomiting, and bloating. In some cases, it can lead to more serious conditions such as gastritis, peptic ulcer disease, and stomach cancer. Testing for H. pylori is important to diagnose and treat the infection. Several methods are used to test H. pylori, Including blood test, breath test, stool test, and endoscopy test.
Blood tests detect antibodies against H. pylori in the bloodstream, while breath tests measure the presence of carbon dioxide in a patient's breath after ingestion of a special solution. Stool tests detect H. pylori antigens in a patient's stool, while endoscopy with biopsy involves taking a small tissue sample from the stomach lining for laboratory analysis. The global Helicobacter pylori diagnostics market is majorly driven by an Increase in prevalence of infectious diseases such as gastric cancer, rise in advancements in technology to diagnose H. pylori infection, and surge in awareness about H. pylori testing. Rise in advances in diagnostic technology have made it easier and more efficient to detect H. pylori infection, which drives the demand for diagnostic tests and supports the market growth. For instance, breath tests are non-invasive tests that detect H. pylori by measuring the presence of carbon dioxide in a patient's breath. This test is highly accurate and can be performed in a doctor's office.
In addition, rapid urease tests are diagnostic tests that detect H. pylori by measuring the enzyme urease, which is produced by the bacteria. These tests are quick & easy to perform and provide results in as little as 30 minutes. These advances in diagnostic technology drive the growth of the Helicobacter pylori diagnostics market. Furthermore, surge in demand for point-of-care testing allows rapid and accurate diagnosis of the infection without the need for laboratory testing, which drives the demand for H. pylori testing and supports the market growth. However, the lack of awareness about H. pyloric infection and availability of advanced diagnostic tests and shortage of skilled professionals to diagnostic tests in developing countries are the factors that restrain the market growth.
The Helicobacter pylori diagnostics market is segmented into test type, method, end user, and region. By test type, the market is divided into non-invasive test and invasive test. Non-invasive test segment is further categorized into the serology test, stool antigen test, and carbon urea breath test. By method, the market is bifurcated into laboratory-based tests and point of care test. By end user, the market is classified into hospitals, diagnostics laboratories, and others. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global Helicobacter pylori diagnostics market are Abbott Laboratories, Avanos Medical, Inc., Biohit Oyj, Bio-Rad Laboratories, Inc., Cardinal Health Inc., F. Hoffmann-La Roche Ltd., Gulf Coast Scientific, Meridian Bioscience, Inc., Quidel Corporation, and Thermo Fisher Scientific Inc. Key players operating in the market have adopted product approval, acquisition, and agreement as their key strategies to expand their product portfolio.
Blood tests detect antibodies against H. pylori in the bloodstream, while breath tests measure the presence of carbon dioxide in a patient's breath after ingestion of a special solution. Stool tests detect H. pylori antigens in a patient's stool, while endoscopy with biopsy involves taking a small tissue sample from the stomach lining for laboratory analysis. The global Helicobacter pylori diagnostics market is majorly driven by an Increase in prevalence of infectious diseases such as gastric cancer, rise in advancements in technology to diagnose H. pylori infection, and surge in awareness about H. pylori testing. Rise in advances in diagnostic technology have made it easier and more efficient to detect H. pylori infection, which drives the demand for diagnostic tests and supports the market growth. For instance, breath tests are non-invasive tests that detect H. pylori by measuring the presence of carbon dioxide in a patient's breath. This test is highly accurate and can be performed in a doctor's office.
In addition, rapid urease tests are diagnostic tests that detect H. pylori by measuring the enzyme urease, which is produced by the bacteria. These tests are quick & easy to perform and provide results in as little as 30 minutes. These advances in diagnostic technology drive the growth of the Helicobacter pylori diagnostics market. Furthermore, surge in demand for point-of-care testing allows rapid and accurate diagnosis of the infection without the need for laboratory testing, which drives the demand for H. pylori testing and supports the market growth. However, the lack of awareness about H. pyloric infection and availability of advanced diagnostic tests and shortage of skilled professionals to diagnostic tests in developing countries are the factors that restrain the market growth.
The Helicobacter pylori diagnostics market is segmented into test type, method, end user, and region. By test type, the market is divided into non-invasive test and invasive test. Non-invasive test segment is further categorized into the serology test, stool antigen test, and carbon urea breath test. By method, the market is bifurcated into laboratory-based tests and point of care test. By end user, the market is classified into hospitals, diagnostics laboratories, and others. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global Helicobacter pylori diagnostics market are Abbott Laboratories, Avanos Medical, Inc., Biohit Oyj, Bio-Rad Laboratories, Inc., Cardinal Health Inc., F. Hoffmann-La Roche Ltd., Gulf Coast Scientific, Meridian Bioscience, Inc., Quidel Corporation, and Thermo Fisher Scientific Inc. Key players operating in the market have adopted product approval, acquisition, and agreement as their key strategies to expand their product portfolio.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the helicobacter pylori diagnostics market analysis from 2022 to 2032 to identify the prevailing helicobacter pylori diagnostics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the helicobacter pylori diagnostics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report Includes the analysis of the regional as well as global helicobacter pylori diagnostics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Test Type
- Non-Invasive Test
- Type
- Serology Test
- Stool Antigen Test
- Carbon Urea Breath Test
- Invasive Test
By Method
- Laboratory Based Test
- Point of Care Test
By End User
- Diagnostics Laboratories
- Others
- Hospitals
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Avanos Medical, Inc.
- Gulf Coast Scientific
- Bio-Rad Laboratories, Inc.
- Biohit Oyj
- Thermo Fisher Scientific Inc.
- Cardinal Health Inc.
- Quidel Corporation
- Meridian Bioscience, Inc.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: HELICOBACTER PYLORI DIAGNOSTICS MARKET, BY TEST TYPE
CHAPTER 5: HELICOBACTER PYLORI DIAGNOSTICS MARKET, BY METHOD
CHAPTER 6: HELICOBACTER PYLORI DIAGNOSTICS MARKET, BY END USER
CHAPTER 7: HELICOBACTER PYLORI DIAGNOSTICS MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to a new report, titled, 'Helicobacter Pylori Diagnostics Market,' The helicobacter pylori diagnostics market was valued at $552.65 million in 2022, and is estimated to reach $926.8 million by 2032, growing at a CAGR of 5.3% from 2023 to 2032.The Helicobacter Pylori Diagnostics Market is likely to experience a significant growth rate of 5.3% from 2023-2032 owing to increase in demand for H.pylori testing from diagnostics and biotech sector.
Helicobacter pylori diagnostics refers to the process of detecting the presence of the bacterium Helicobacter pylori (H. pylori) in a patient's stomach or gastrointestinal tract. H. pylori is a common bacterial infection that can cause a range of digestive problems, including gastritis, peptic ulcers, and even stomach cancer. Testing for H. pylori infection is important for accurate diagnosis and appropriate treatment of these conditions.
Key factors driving the growth of the Helicobacter pylori diagnostics market include rise in the prevalence of infectious diseases such as stomach cancer, gastritis, and peptic ulcers, rise in demand for non-invasive diagnostic procedures, and development of new and improved testing methods for H. pylori testing. Helicobacter pylori is a type of bacteria that causes infection in the stomach, and it is the main cause of peptic ulcers. Thus, rise in cases of peptic ulcer drives the market growth. For instance, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIH), about 30% to 40% of people in the U.S. had H. pylori infection in 2021.
In addition, the rise of point-of-care testing (POCT) technology is contributing to the growth of the Helicobacter pylori diagnostics market. POC tests can be performed in primary care settings and offer faster turnaround times, increased accessibility to patients, and lower costs. This led to a rise in demand for H. pylori testing, and further boosting the market growth. Furthermore, significant advancements in the H. pylori diagnostic technologies, including non-invasive testing methods such as the urea breath test, stool antigen test, and serology. These advances have made H. pylori testing more accessible and convenient for patients, thereby driving the growth of the market.
The market also offers growth opportunities to the key players in the market. Rise in the demand for point of care testing for H. pylori due to its faster turnaround time and increased accessibility to patients led to a rise in testing among citizens, which provides lucrative opportunity for market growth. Non-invasive H. pylori diagnostic tests, such as IgG serology, urea breath test (UBT), and monoclonal stool antigen test are available for point-of-care (POC) testing, which can be performed in primary care settings. Thus, introduction of a new point of care testing technologies has resulted in a rise in demand for H. pylori testing and there is diversity in available clinical applications, which propels the Helicobacter pylori diagnostics market growth.
The Helicobacter pylori diagnostics market is segmented into test type, method, end user, and region. On the basis of test type, the market is categorized into non-invasive test and invasive test. The non-invasive test segment is further categorized into the serology test, stool antigen test, and carbon urea breath test. On the basis of method, it is bifurcated into laboratory-based tests and point of care test. On the basis of end user, it is segmented into hospitals, dental clinics, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The key players profiled in the study include Abbott Laboratories, Avanos Medical, Inc., Biohit Oyj, Bio-Rad Laboratories, Inc., Cardinal Health Inc., F. Hoffmann-La Roche Ltd., Gulf Coast Scientific, Meridian Bioscience, Inc., Quidel Corporation, and Thermo Fisher Scientific Inc. The players in the market have been actively engaged in the adoption of various strategies such as product approval, acquisition, and agreement to remain competitive and gain an advantage over the competitors in the market. For instance, in July 2021, Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced that it signed a definitive agreement to acquire the North American BreathTek business from Otsuka America Pharmaceutical, Inc.
Key Market Insights (Updated)
-By test type, the non-Invasive test segment was the largest revenue contributor to the market and is estimated to reach $562.62 million by 2032, with a highest CAGR of 5.6%.
-By method, the laboratory-based test segment dominated the global market in 2022. However, the point of care test segment is expected to be the fastest-growing segment with a CAGR of 6.5% during the forecast period.
-Based on end user, the diagnostics laboratories segment was the largest revenue contributor to the market in 2022. However, the others segment is expected to be the fastest-growing segment with a CAGR of 6.5% during the forecast period.
-Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Avanos Medical, Inc.
- Gulf Coast Scientific
- Bio-Rad Laboratories, Inc.
- Biohit Oyj
- Thermo Fisher Scientific Inc.
- Cardinal Health Inc.
- Quidel Corporation
- Meridian Bioscience, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
